Interferon-α has been used as standard therapy for patients with Philadelphia-positive
chronic myeloid leukemia (CML) for more than 20 years. Recently randomized trials have …

Imatinib mesylate (Gleevec)(formerly STI571) has secured a definitive role in the treatment
of chronic myeloid leukemia (CML) due to its specificity and efficacy. Although some patients …

Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a
BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid …

We reviewed 261 patients with chronicphase chronic myelogenous leukemia (CML) after
interferon-α (IFN-α) failure treated with imatinib mesylate 400 mg daily. With a median follow …

The discovery of molecularly targeted agents that selectively inhibit bcr-abl tyrosine kinase
activity, such as imatinib, has revolutionized the treatment and natural history of chronic …

We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid
leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to …

Through sequencing analysis of blood or bone marrow samples from patients with chronic
myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients …

Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a
single genetic abnormality, characterized by a reciprocal translocation involving …

While imatinib (400 mg daily) results in 12 mo complete cytogenetic responses (CCyR) in
76% of pt, complete molecular responses (CMR) at this time are in the range of 4–6%. A …

Chronic myeloid leukemia (CML) is caused by Bcr-Abl, a constitutively active tyrosine kinase
that is the result of a reciprocal translocation between chromosomes 9 and 22 and …